Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors: ##STR00001## wherein: A represents a group selected from one of the following: (CH.sub.2).sub.t--, --(CH.sub.2)--S(O).sub.z--, or --S(O).sub.z--(CH.sub.2)--, B is a heteroaryl, optionally substituted; R is a group selected from the following: alkyl, aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other; R' is a group selected from the following: an ether group of formula --(CH.sub.2)--O--(CH.sub.2).sub.v--R'', a ketonic group of formula --C(O)-Z', a substituent having an hydroxyl function of formula --CH(OH)-Z'; and an amide substituent of formula --C(O)--NH-T'.